Press release
Press release
Maidenhead, UK: August 11, 2008, Sense Proteomic Ltd today announced that it has expanded its biomarker IP portfolio through filing a patent covering a novel panel of biomarkers for the early diagnosis of Systemic Lupus Erythematosus (Lupus).
The Lupus biomarker panel has been developed using Sense Proteomic's proprietary protein array technology that permits rapid identification of autoantibody biomarkers for cancer and autoimmune diseases.
Referring to the patent filing, Rachel Fallon, joint CEO, said, "We expect this biomarker panel to make a real difference in disease outcome for patients. In addition to facilitating the development of new drug treatments for Lupus, it should greatly improve the early diagnosis of the disease and lead to better control and management of Lupus through improved patient monitoring both within clinical practice and within clinical trials."
Lupus is a chronic autoimmune disease resulting in inflammation and tissue damage. It can affect any part of the body but most often affects the skin, blood, joints and kidneys, proving fatal in some patients. It progresses through unpredictable rounds of remission and flares of the disease which can be of differing levels of severity. Although currently there is no cure for Lupus the disease can be treated symptomatically with immunosupresants and corticosteroids. The Lupus Foundation of America (LFA) estimates that Lupus affects between 1,500,000 and 2,000,000 people in the USA with the incidence in women being substantially higher than in men.
Sense Proteomic Limited is a biomarker discovery company utilising its proprietary protein array technology to discover and commercialise autoantibody biomarkers for cancer and autoimmune diseases.
Rachel Fallon - Joint CEO
Sense Proteomic Limited
Tel: +44 (0)1628 513 500
rachel.fallon@senseproteomic.com